BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17621799)

  • 1. [Treatment of rheumatoid arthritis (RA) with anticytokines].
    Feuchtenberger M; Kneitz C; Tony HP
    MMW Fortschr Med; 2006 Oct; 148(42):44-5, 47. PubMed ID: 17621799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological therapies for rheumatoid arthritis.
    Edwards CJ
    Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiating the efficacy of tumor necrosis factor inhibitors.
    Haraoui B
    J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab treatment of rheumatoid arthritis.
    Maini SR
    Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF inhibitors in the treatment of arthritis.
    Lorenz HM
    Curr Opin Investig Drugs; 2000 Oct; 1(2):188-93. PubMed ID: 11249572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN;
    N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Present importance of direct immunologically based intervention strategies using anticytokines in rheumatoid arthritis].
    Boehme MW; Gao IK
    Z Rheumatol; 1999 Oct; 58(5):251-66. PubMed ID: 10591973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L; Lapadula G; Mathieu A
    BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of rheumatoid arthritis with etanercept.
    Genovese MC; Kremer JM
    Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
    Bondeson J; Maini RN
    Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
    Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN
    Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma.
    Sarzi-Puttini P; Atzeni F; Shoenfeld Y; Ferraccioli G
    Autoimmun Rev; 2005 Mar; 4(3):153-61. PubMed ID: 15823501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF inhibitors - new and old agents for rheumatoid arthritis.
    Simsek I
    Bull NYU Hosp Jt Dis; 2010; 68(3):204-10. PubMed ID: 20969553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists.
    Kary S; Worm M; Audring H; Huscher D; Renelt M; Sörensen H; Ständer E; Maass U; Lee H; Sterry W; Burmester GR
    Ann Rheum Dis; 2006 Mar; 65(3):405-7. PubMed ID: 16150791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].
    Manger B; Michels H; Nüsslein HG; Schneider M; Sieper J;
    Z Rheumatol; 2007 Feb; 66(1):72-5. PubMed ID: 17221253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.